In the following video, Motley Fool health care bureau chief Brenton Flynn discusses an interesting takeaway from the JPMorgan conference yesterday. While there are already options for investors to invest directly in the diabetes space, one thing that caught his eye was a potential indirect diabetes play, in the form of Dynavax's (DVAX +0.00%) hepatitis-B vaccine. While the vaccine is not yet approved, the CDC's Advisory Committee on Immunization Practices recommended in 2011 that all diabetes patients between the ages of 19 and 59 be vaccinated against hepatitis B, which could double or potentially triple Dynavax's existing market opportunity for the vaccine.
